Xeris Biopharma (NASDAQ:XERS) Director Sells $91,450.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Marla Persky sold 15,500 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $5.90, for a total value of $91,450.00. Following the transaction, the director directly owned 126,500 shares in the company, valued at $746,350. The trade was a 10.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Stock Up 0.5%

NASDAQ:XERS traded up $0.03 on Friday, hitting $6.18. 1,028,207 shares of the company’s stock traded hands, compared to its average volume of 1,829,779. The company has a market cap of $1.07 billion, a PE ratio of 103.00 and a beta of 0.78. Xeris Biopharma Holdings, Inc. has a 1 year low of $4.30 and a 1 year high of $10.08. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00. The firm has a 50-day moving average price of $6.08 and a 200-day moving average price of $6.60.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. The business had revenue of $83.13 million during the quarter, compared to analyst estimates of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. Equities analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Wall Street Zen upgraded shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Xeris Biopharma in a research note on Monday, March 2nd. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Xeris Biopharma has an average rating of “Hold” and an average target price of $10.80.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Kestra Advisory Services LLC bought a new position in Xeris Biopharma in the 4th quarter worth $25,000. KBC Group NV acquired a new stake in shares of Xeris Biopharma in the first quarter valued at about $27,000. AlphaQuest LLC acquired a new stake in shares of Xeris Biopharma in the third quarter valued at about $35,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Xeris Biopharma by 9,276.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after purchasing an additional 7,421 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Xeris Biopharma by 29.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after purchasing an additional 1,820 shares during the period. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.